RxDoctor Payments Data

Ambereen Ghani, MD

Family Medicine · Schaumburg, ILNPI 1548468127

Payments from drug & device makers

$15,169in general payments, 2019–2025

Across 663 payments — averaging $22.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Amgen$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$894
  • Pfizer$771
  • plus $6K from 37 others

What the payments were for

  • Food & beverage$15,01899%
  • Education$1511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,169 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$112,278
Medicare patients
301
Services billed
952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol284$274,628
JardianceEmpagliflozin218$246,406
OzempicSemaglutide153$178,463
IngrezzaValbenazine Tosylate22$102,383
JanuviaSitagliptin Phosphate99$97,824
LinzessLinaclotide80$75,744
VascepaIcosapent Ethyl101$72,003
RybelsusSemaglutide36$51,560
TrulicityDulaglutide41$47,766
EliquisApixaban54$46,011
MounjaroTirzepatide34$43,749
MyrbetriqMirabegron40$40,250
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog34$31,185
Soliqua 100-33Insulin Glargine/Lixisenatide12$23,858
Breo ElliptaFluticasone/Vilanterol48$23,673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$3,088$286,336306 claims
Boehringer IngelheimJardiance, Tradjenta$210$254,803229 claims
Novo NordiskOzempic, Rybelsus$894$230,023189 claims
MerckJanuvia$91$97,82499 claims
Lilly USA, LLCTrulicity, Mounjaro$1,089$91,51575 claims
AbbVieLinzess$1,271$75,74480 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$618$48,28489 claims
PfizerEliquis$771$46,01154 claims
Astellas Pharma US IncMyrbetriq$443$40,25040 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$41$23,85812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Schaumburg

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →